184710-75-6

Basic information

• Product Name: 2-(3-benzyloxycarbonylamino-5-benzyl-2-oxo-1,2-dihydro-1-pyridyl)acetic acid
• Synonyms: 2-(3-benzyloxycarbonylamino-5-benzyl-2-oxo-1,2-dihydro-1-pyridyl)acetic acid
• CAS NO: 184710-75-6
• Molecular Weight: 392.411
• Mol File: 184710-75-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(3-benzyloxycarbonylamino-5-benzyl-2-oxo-1,2-dihydro-1-pyridyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-benzyloxycarbonylamino-5-benzyl-2-oxo-1,2-dihydro-1-pyridyl)acetic acid(184710-75-6)
• EPA Substance Registry System: 2-(3-benzyloxycarbonylamino-5-benzyl-2-oxo-1,2-dihydro-1-pyridyl)acetic acid(184710-75-6)

Safety Data

• Hazardous Substances Data: 184710-75-6(Hazardous Substances Data)

Upstream product

• 147283-71-4 5-Benzyl-3-benzyloxycarbonylamino-pyrid-2-one 
• 147269-68-9 3-<<(benzyloxy)carbonyl>amino>-5-iodopyrid-2-one 
• 147269-67-8 3-(benzyloxycarbonylamino)pyrid-2-one 
• 33630-99-8 3-amino-2-pyridone 
• 6332-56-5 3-nitropyridone 
• 147283-72-5 (5-Benzyl-3-benzyloxycarbonylamino-2-oxo-2H-pyridin-1-yl)-acetic acid ethyl ester 

Downstream Products

• 147267-87-6 2-(5-Benzyl-3-benzyloxycarbonylamino-2-oxo-1,2-dihydro-1-pyridyl)-N-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide 
• 147268-12-0 N-{5-Benzyl-2-oxo-1-[(3,3,3-trifluoro-1-isopropyl-2-oxo-propylcarbamoyl)-methyl]-1,2-dihydro-pyridin-3-yl}-oxalamic acid methyl ester 
• 147313-63-1 2-(3-Amino-5-benzyl-2-oxo-2H-pyridin-1-yl)-N-(3,3,3-trifluoro-1-isopropyl-2-oxo-propyl)-acetamide 
• 147283-69-0 {5-Benzyl-2-oxo-1-[(3,3,3-trifluoro-2-hydroxy-1-isopropyl-propylcarbamoyl)-methyl]-1,2-dihydro-pyridin-3-yl}-carbamic acid benzyl ester 

Relevant articles and documents

HETEROCYCLIC AMIDE COMPOUNDS AND PHARMACEUTICAL USE OF THE SAME

Heterocyclic amide compounds of the formula (I) STR1 wherein each symbol is as defined in the specification, pharmacologically acceptable salts thereof, pharmaceutical compositions thereof and pharmaceutical use thereof. The heterocyclic amide compounds and pharmacologically acceptable salts thereof of the present invention have superior inhibitory activity against chymase groups in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be effective for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.